ArticleBMC anesthesiology2026
Dexmedetomidine-remifentanil-assisted awake videolaryngoscopic intubation in a patient with Madelung disease and compensated liver cirrhosis undergoing prone lumbar spine surgery: a case report.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMadelung disease (multiple symmetric lipomatosis) is a rare metabolic disorder characterized by progressive accumulation of non-encapsulated lipomatous tissue in the cervical and parapharyngeal regions, which can critically distort upper airway anatomy and substantially increase the risk of failed intubation. When a difficult airway is anticipated, awake tracheal intubation (ATI) is recommended. Videolaryngoscopy (VL) is increasingly recognized as an evidence-based alternative to fiberoptic bronchoscopy (FOB) in selected patients with supraglottic soft-tissue crowding; however, its use in combination with pharmacologic sedation in patients with concurrent hepatic dysfunction has not been previously described. CASE PRESENTATION: A 70-year-old man with Madelung disease and compensated liver cirrhosis (Child-Pugh class A) was scheduled for posterior lumbar decompression and fusion at the L4-5 level in the prone position. Preoperative flexible nasopharyngolaryngoscopy confirmed significant supraglottic crowding with partial obscuration of the epiglottic inlet caused by perilaryngeal lipomatous infiltration, without intrinsic glottic pathology. In the operating room, multimodal topical anesthesia with 10% lidocaine spray was combined with cooperative sedation using dexmedetomidine (loading dose 1.0 µg/kg over 10 min, maintenance infusion 0.5 µg/kg/h) and remifentanil (0.05 µg/kg/min), titrated to Patient State Index (PSI) values of 70-85 with preserved spontaneous ventilation. Orotracheal intubation with a McGrath™ MAC videolaryngoscope (size 3 blade) was achieved on the first attempt without hypoxemia, coughing, or hemodynamic instability. General anesthesia, the intraoperative course, and extubation were completed without airway-related complications. The patient was discharged on postoperative day 16.
conclusionsThis case demonstrates that awake VL combined with dexmedetomidine-remifentanil sedation and topical anesthesia is a safe and effective approach in Madelung disease when airway compromise is caused by supraglottic soft-tissue crowding. Remifentanil is the preferred opioid adjunct in patients with hepatic dysfunction owing to its hepatic-independent elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.